The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Murkamilov I.T.

Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan;
Kyrgyz Russian Slavic University named after the First President of Russia B.N. Yeltsin, Bishkek, Kyrgyzstan

Sabirov I.S.

Kyrgyz- Russian Slavic University named after the First President of Russia B.N. Yeltsin, Bishkek, Kyrgyzstan

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Murkamilova J.A.

Family Medicine Center №7, Bishkek, Kyrgyzstan

Aitbaev K.A.

Scientific and Research Institute of Molecular biology and medicine, Bishkek, Kyrgyzstan

Rayimzhanov Z.R.

Burdenko Military Clinical Hospital, Ministry of Defense of Russia, Moscow, Russia

Evaluation of nephrocerebral risk with the use of cystatin C in patients with chronic kidney disease

Authors:

Murkamilov I.T., Sabirov I.S., Fomin V.V., Murkamilova J.A., Aitbaev K.A., Rayimzhanov Z.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(9): 10‑16

DOI: 10.17116/jnevro201811809110

Read: 1061 times

Download PDF (RU)
Contact the author
Table of contents

EVALUATION OF NEPHROCEREBRAL RISK WITH THE USE OF CYSTATIN C IN PATIENTS WITH CHRONIC KIDNEY DISEASE
EVALUATION OF NEPHROCEREBRAL RISK WITH THE USE OF CYSTATIN C IN PATIENTS WITH CHRONIC KIDNEY DISEASE

To cite this article:

Murkamilov IT, Sabirov IS, Fomin VV, Murkamilova JA, Aitbaev KA, Rayimzhanov ZR. Evaluation of nephrocerebral risk with the use of cystatin C in patients with chronic kidney disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(9):10‑16. (In Russ.)
https://doi.org/10.17116/jnevro201811809110

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Functional state of the kidneys in patients with various types of cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):105-111
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
Asse­ssment of risk of deve­loping fractures and sarcopenia and quality of life of patients with chro­nic kidney disease at the outpatient stage. Russian Journal of Preventive Medi­cine. 2024;(12):88-91
Reco­mmendations for the reha­bilitation of patients with chro­nic kidney disease requiring hemo­dialysis (literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):62-73
Inci­dence of diseases of the circulatory system in the working-age popu­lation of the Ural Fede­ral District in 2012—2022. Russian Journal of Preventive Medi­cine. 2025;(1):24-29
Prevalence of cere­brovascular diseases risk factors acco­rding to the cohort survey data in Bishkek, Kyrgyz Repu­blic. Russian Journal of Preventive Medi­cine. 2025;(3):34-39
Asso­ciations between the gut microbiota-derived meta­bolites with the para­meters of 24-hour ambu­latory blood pressure moni­toring in patients on maintenance hemo­dialysis. Russian Journal of Preventive Medi­cine. 2025;(3):96-102
Difficulties in differential diagnosis of pulmonary dissemination. Journal of Respiratory Medi­cine. 2025;(2):79-82
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Abstract:

Objective. To study a role of cystatin C in the nephrocerebral risk in chronic kidney disease at the initial stage of the disease. Material and methods. One hundred and twenty-eight patients (63 men and 65 women) with chronic kidney disease (CKD) were examined at the pre-dialysis stage of the disease. All patients underwent a complex clinical and laboratory examination with determination of the lipid spectrum, uric acid, fibrinogen, calcium and cystatin C, and subsequent calculation of the glomerular filtration rate (GFR). To assess structural changes in carotid arteries, ultrasound dopplerography was performed. Depending on the thickness of the intima-media (TIM), the entire sample is divided into CKD groups with no signs of carotid atherosclerosis (SC), n=70 and on CKD with SC, n=58. Results. Patients of the second group (CKD with SC), had higher body mass index (p<0.05), systolic (p<0.05) and central (p<0.05) arterial pressure (BP) and blood cystatin C (p<0.05). In the same group, there was a significant decrease in the concentration of high-density lipoprotein cholesterol (p<0.05) compared with those of the first group (CKD). The age of patients and the content of cystatin C (p<0.05) influenced the increase in TIM. Significant positive correlations between cystatin C content and TIM, systolic and diastolic blood pressure (p<0.05), and a negative correlation cystatin C content and GFR were noted in patients of the second group. Conclusion. The increase in the level of cystatin C in blood plasma in CKD indicates the development of structural changes in the carotid arteries, the increase in the levels of systolic and central arterial pressure, the decrease in the concentration of HDL cholesterol, which is associated with significant inhibition of GFR.

Keywords:

chronic kidney disease
cystatin C
thickness of intima-media
cerebrovascular diseases

Authors:

Murkamilov I.T.

Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan;
Kyrgyz Russian Slavic University named after the First President of Russia B.N. Yeltsin, Bishkek, Kyrgyzstan

Sabirov I.S.

Kyrgyz- Russian Slavic University named after the First President of Russia B.N. Yeltsin, Bishkek, Kyrgyzstan

Fomin V.V.

I.M. Sechenov First State Moscow Medical University

Murkamilova J.A.

Family Medicine Center №7, Bishkek, Kyrgyzstan

Aitbaev K.A.

Scientific and Research Institute of Molecular biology and medicine, Bishkek, Kyrgyzstan

Rayimzhanov Z.R.

Burdenko Military Clinical Hospital, Ministry of Defense of Russia, Moscow, Russia

Close metadata

References:

  1. Muhin NA. Nefrologija. Nacional’noe rukovodstvo. Kratkoe izdanie. M. 2016. (In Russ.)
  2. Fomin VV, Rogova IV, Damulin IV, Muhin NA. Osobennosti formirovanija kognitivnyh rasstrojstv na dodializnyh stadijah hronicheskoj bolezni pochek. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115(12):25-30. (In Russ.)
  3. Locatelli F, Pozzoni P, Tentori F, Del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2003;18:7:2-9. https://doi.org/10.1093/ndt/gfg1072
  4. Lainščak M. Cardiovascular Risk in Chronic Kidney Disease. EJIFCC. 2009;20:1:73-76. PMCID: PMC4975273.
  5. Moiseev VS, Muhin NA, Smirnov AV, Kobalava ZhD, Bobkova IN, Villeval’de SV, Efremovceva MA, Kozlovskaja LV, Shvecov MYu, Shestakova MV. Serdechno-sosudistyj risk i hronicheskaja bolezn’ pochek: strategii kardio-nefroprotekcii. Klinicheskaja farmakologija i terapija. 2014;3:4-27. (In Russ.)
  6. KDIGO, 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-136.
  7. Stein JL, Korcarz CE. American society of Echocardoigraphy carotid Intima-Media Thickness Task Force. J Am soc Echocardiography. 2008;21:93-111. https://doi.org/10.1016/j.echo.2007.11.011
  8. Akchurin RS, Vasjuk YuA, Karpov YuA, Lupanov VP, Marcevich SYu, Pozdnjakov YuM, Savchenko AP, Jakushin SS, Urinskij AM, Abugov SA, Alekjan BG, Anikin VV, Aronov DM, Ahmedzhanov NM, Belenkov YuN, Belousov YuB, Bojcov S., Bochorishvili ML, Buziashvili YuI, Volkov BC, Gabinskij YaL, Galjavich AS, Glezer MG, Gracianskij NA, Gorbachenkov AA, Grinshtejn YuI, Gurevich MA, Dovgalevskij PYa, Drapkina OM, Zharova EA, Zadionchenko VS, Kalinina AM, Karpov RS, Kirichenko AA, Koltunov IE, Krjukov NN, Kuharchuk VV, Lazebnik LB, Liferov RA, Lopatin YuM, Ljusov VA, Ljakishev AA, Mazaev VP, Makolkin VI, Martynov AI, Matjushin EV, Miljagin VA, Moiseev VS, Naumcheva NN, Nedogoda SV, Nedbajkin AM, Nikitin YuP, Oganov RG, Perepech NB, Pogosova NV, Popov LV, Platonov DYu, Ruda MYa, Savenkov MP, Samorodskaja IV, Samko AN, Sidorenko BA, Skibickij VV, Storozhakov GI, Syrkin AL, Terent’ev VP, Tuev AV, Tjurin VP, Shabalkin BV, Shal’nova SA, Shirjaev AA, Shljahto EV, Cherkavskaja OV, Jakusevich VV. Nacional’nye rekomendacii po diagnostike i lecheniju stabil’noj stenokardii. Kardiovaskuljarnaja terapija i profilaktika. 2008;7(6):1-37. (In Russ.)
  9. Parfenov AS. Jekspress diagnostika serdechno-sosudistyh zabolevanij. Mir izmerenij. 2008;6:74-82. (In Russ.)
  10. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18(10):2024-2031. https://doi.org/10.1093/ndt/gfg349
  11. Grinhal’h T. Osnovy dokazatel’noj mediciny. M.: GJeOTAR-MED; 2004. (In Russ.)
  12. Murkamilov IT, Ajtbaev KA, Sabirov IS, Fomin VV, Jusupov FA. Hronicheskaja bolezn’ pochek i serdechno-sosudistye oslozhnenija: fokus na central’noe arterial’noe davlenie. Sistemnye gipertenzii. 2017;1(14):58-60. (In Russ.)
  13. Muhin NA, Kozlovskaja LV, Bobkova IN, Plieva OK, Chebotareva NV, Shherbak AV. Induciruemye proteinuriej mehanizmy remodelirovanija tubulointersticija i vozmozhnosti nefroprotekcii pri glomerulonefrite. Vestnik Rossijskoj Akademii medicinskih nauk. 2005;1:3-8. (In Russ.)
  14. Fomin VV, Kozlovskaja LV, Milovanov YuS. Anemicheskaja kardiomiopatija pri hronicheskoj bolezni pochek: rol’ jeritropojetina-beta. Klinicheskaja nefrologija. 2011;6:48-51. (In Russ.)
  15. Volgina G, Shtandel’ V, Balkarova O, Lovchinskij E. Giperfosfatemija pri hronicheskoj bolezni pochek: sovremennaja strategija korrekcii. Vrach. 2012;7:19-23. (In Russ.)
  16. Rudenko TE, Kutyrina IM, Shvecov MYu. Faktory riska remodelirovanija miokarda na II-IV stadii hronicheskoj bolezni pochek. Terapevticheskij arhiv. 2012;6:21-26. (In Russ.)
  17. Serov VA, Shutov AM, Troshen’kina OV, Makeeva ER, Serova DV, Kuznetsova YuS. Osobennosti sutochnogo profilya arterial’nogo davleniya u bol’nykh s khronicheskoi serdechnoi nedostatochnost’yu pri narushenii funktsii pochek. Nefrologiya. 2011;4(15):39-44. (In Russ.)
  18. Tomilina NA. Khronicheskaya bolezn' pochek. Izbrannye glavy nefrologii. GEOTAR-Media; 2017.
  19. National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. Am J Kidney Dis. 2002;39(suppl 1):1-266.
  20. KDIGO 2017. Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease — Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements. 2017;7(1):1-59. https://doi.org/10.1016/j.kisu.2017.04.001
  21. Vel’kov VV. Tsistatin S i NGAL-markery preklinicheskoi renal’noi disfunktsii i subklinicheskogo ostrogo povrezhdeniya pochek. Laboratornaya sluzhba. 2015;2:38-43. (In Russ.)
  22. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG. Cystatin C identifies chronic kidney disease patients at higher risk for complications. Journal of the American Society of Nephrology. 2011;22:1:147-155. https://doi.org/10.1681/ASN.2010050483
  23. Salgado JV, França AK, Cabral NA, Lages J, Ribeiro VS, Santos AM, Salgado BJ. Cystatin C, kidney function, and cardiovascular risk factors in primary hypertension. Revista da Associação Médica Brasileira. 2013;59:1:21-27. https://doi.org/10.1590/S0104-42302013000100007
  24. Luo J, Wang LP, Hu HF, Zhang L, Li YL, Ai LM, Mu HY. Cystatin C and cardiovascular or all-cause mortality risk in the general population: a meta-analysis. Clinica Chimica Acta. 2015;450:39-45. https://doi.org/10.1016/j.cca.2015.07.016
  25. Liu P, Sui S, Xu D. Clinical analysis of association of cystatin c and atrial fibrillation. Russian Journal of Cardiology. 2014;(4-ENG):34-38. https://doi.org/10.15829/1560-4071-2014-4-ENG-34-38
  26. Kobayashi T, Yokokawa H, Fujibayashi K, Haniu T, Hisaoka T, Fukuda H, Naito T. Association between high cystatin C levels and carotid atherosclerosis. World Journal of Cardiology. 2017;9(2):174-181. https://doi.org/10.4330/wjc.v9.i2.174
  27. Xu Z, Leng C, Yang B, Wang H, Sun J, Liu Z, Yang L, Ge W, Zhu J. Serum cystatin C is associated with large cerebral artery stenosis in acute ischemic stroke. Oncotarget. 2017;22:8(40):67181-67188. https://doi.org/10.18632/oncotarget.18061
  28. Kim TJ, Kang MK, Jeong HG, Kim CK, Kim Y, Nam KW. Cystatin C is a useful predictor of early neurological deterioration following ischaemic stroke in elderly patients with normal renal function. European Stroke Journal. 2016;2(1):23-30. https://doi.org/10.1177/2396987316677197
  29. Kirillova NCh. Sravnitel’noe issledovanie kontsentratsii tsistatina s krovi patsientov s ostrym koronarnym sindromom, ostrym narusheniem mozgovogo krovoobrashcheniya i terminal’noi pochechnoi nedostatochnost’yu. Doktor.Ru. 2015;8-9(109-110):28-32. (In Russ.)
  30. Hashimoto N, Nishiyama S, Watanabe T, Wanezaki M, Yamaura G, Arimoto T, Takahashi H, Shishido T, Miyamoto T, Kubota I. Abstract 13956: Cystatin C Based Estimated Glomerular Filtration Rate is a Feasible Parameter for Incident Stroke in Patients With Atrial Fibrillation. Circulation. 2015;132:A13956.
  31. Huang R, Gu J, Cao Q, Ma J, Gu W, Fan Z. The association between serum cystatin C and carotid intima—media thickness in metabolic syndrome patients with normal estimated glomerular filtration rate. Clinica Chimica Acta. 2015;448:170-173. https://doi.org/10.1016/j.cca.2015.07.005
  32. Urbonaviciene G, Shi GP, Urbonavicius S, Henneberg EW, Lindholt JS. Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis. 2011;216(2):440-445. https://doi.org/10.1016/j.atherosclerosis.2011.02.016
  33. Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, Satterfield S, Atkinson H, Windham BG, Kurella-Tamura M. Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol. 2008;63:798-802. https://doi.org/10.1002/ana.21383
  34. Wada M, Nagasawa H, Kawanami T, Kurita K, Daimon M, Kubota I, Kayama T, Kato T. Cystatin C as an index of cerebral small vessel disease: results of a cross-sectional study in community-based Japanese elderly. Eur J Neurol. 2010;17:383-390. https://doi.org/10.1111/j.1468-1331.2009.02809.x
  35. Seliger SL, Longstreth WT Jr, Katz R, Manolio T, Fried LF, Shlipak M, Stehman-Breen CO, Newman A, Sarnak M, Gillen DL, Bleyer A, Siscovick DS. Cystatin C and subclinical brain infarction. J Am Soc Nephrol. 2005;16:3721-3727. https://doi.org/10.1681/ASN.2005010006
  36. Sabirov IS, Akhmad Nasir, Iskenderova SA. Sostoyanie sonnykh arterii u bol’nykh pozhilogo i starcheskogo vozrasta s ishemicheskoi bolezn’yu serdtsa, oslozhnennoi khronicheskoi serdechnoi nedostatochnost’yu. Vestnik KRSU. 2014;4(14):139-142. (In Russ.)
  37. Ribeiro AH, Lotufo PA, Fujita A, Goulart AC, Chor D, Mill JG, Bensenor IM, Santos IS. Association Between Short-Term Systolic Blood Pressure Variability and Carotid Intima-Media Thickness in ELSA-Brasil Baseline. Am J Hypertens. 2017;1:30(10):954-960. https://doi.org/10.1093/ajh/hpx076
  38. Ferreira JP, Girerd N, Bozec E, Machu JL, Boivin JM, London GM, Zannad F, Rossignol P. Intima-Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population Based Cohort (STANISLAS Cohort Study). Journal of the American Heart Association. 2016;5:6.C.e003529.
  39. Hafner F, Kieninger A, Meinitzer A, Gary T, Froehlich H, Haas E, Hackl G, Eller Ph, Brodmann M, Seinost G. Endothelial dysfunction and brachial intima-media thickness: long term cardiovascular risk with claudication related to peripheral arterial disease: a prospective analysis. PloS One. 2014;9: 4.93357. https://doi.org/10.1371/journal.pone.0093357
  40. Enderle MD, Schroeder S, Ossen R, Meisner C, Baumbach A, Haering HU, Pfohl M. Comparison of peripheral endothelial dysfunction and intimal media thickness in patients with suspected coronary artery disease. Heart. 1998; 80:4:349-354. https://doi.org/10.1136/hrt.80.4.349
  41. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:12:2902-2909. https://doi.org/10.1161/01.STR.0000147965.52712.fa
  42. Dijk JM, van der Graat G, Bots ML, Grobbee DE, Algra A. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J. 2006;24:1971-1978. https://doi.org/10.1093/eurheartj/ehl136
  43. Murkamilov IT, Aitbaev KA, Fomin VV, Yusupov FA. Subklinicheskoe remodelirovanie karotidnykh arterii pri khronicheskom glomerulonefrite. Arkhiv’ vnutrennei meditsiny. 2017;7(4):300-305. (In Russ.) https://doi.org/10.20514/2226-6704-2017-7-4-300-305
  44. Kurella M, Chertow GM, Fried LF, Cummings SR, Harris T, Simonsick E, Satterfield S, Ayonayon H, Yaffe K. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2005;16:2127-2133. https://doi.org/10.1681/ASN.2005010005
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.